Sorafenib: gastrointestinal perforation. Known reactions to VEGF inhibitors.
D020533:Angiogenesis Inhibitors / Q000009:adverse effects; D000911:Antibodies, Monoclonal / Q000009:adverse effects; D001557:Benzenesulfonates / Q000009:adverse effects*; D005060:Europe; D006801:Humans; D007211:Indoles / Q000009:adverse effects; D007416:Intestinal Perforation / Q000139:chemically induced*; D011725:Pyridines / Q000009:adverse effects*; D011758:Pyrroles / Q000009:adverse effects; D040262:Receptors, Vascular Endothelial Growth Factor / Q000187:drug effects
D020533:Angiogenesis Inhibitors; D000911:Antibodies, Monoclonal; D001557:Benzenesulfonates; D007211:Indoles; D011725:Pyridines; D011758:Pyrroles; D040262:Receptors, Vascular Endothelial Growth Factor